Inhibrx Biosciences, Inc.
INBX
Analytical Summary
Inhibrx Biosciences, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.
4-Year Financial Trajectory
AnnualBullish Indicators
- No bullish signals detected.
Bearish Risks
- Debt to EquityDebt to Equity is concerning (bottom quartile)
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Revenue Growth YoY (%) |
550.0%
Excellent
Excellent
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+6775%)
|
-88.9%
Weak
Weak
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Below avg (-1211%)
|
— | — |
| FCF Growth YoY (%) |
37.0%
Excellent
Excellent
Year-over-year change in free cash flow |
20.8%
Good
Good
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Effective Tax Rate (%) (%) |
-0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
0.0%
Excellent
Excellent
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— | — |
| FCF / Net Income (x) |
0.93x
Caution
↑
Caution
Improving
Free cash flow relative to reported net income
Optimal:
> 1x
|
-0.12x
Weak
Weak
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.82x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
-124.4%
Weak
↑
Weak
Improving
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-248.1%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
-69.1%
Weak
Weak
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
-92.2%
Weak
↑
Weak
Improving
Operating profit relative to total assets
Optimal:
> 10%
|
-183.4%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
-71.2%
Weak
Weak
Operating profit relative to total assets
Optimal:
> 10%
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Debt to Equity (x) |
12.58x
Weak
↑
Weak
Improving
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+1997%)
|
0.00x
Excellent
Excellent
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Below avg (-100%)
|
4.76x
Weak
Weak
Total debt relative to shareholder equity
Optimal:
< 0.6x
vs Sector:
Above avg (+693%)
|
— |
| Interest Coverage (x) |
-15.17x
Weak
↑
Weak
Improving
Operating income divided by interest expense
Optimal:
> 5x
|
-28.81x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
-8.21x
Weak
Weak
Operating income divided by interest expense
Optimal:
> 5x
|
— |
| Net Debt (USD) | $-23.66M | $-152.60M | $-70.96M | — |
| Debt / EBITDA (x) |
-0.76x
Excellent
↓
Excellent
Declining
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
0.00x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
-0.95x
Excellent
Excellent
Debt relative to earnings before interest, taxes, depreciation
Optimal:
< 2x
|
— |
| Metric | FY 2025 Dec 31, 2025 10-K ↗ | FY 2024 Dec 31, 2024 10-K ↗ | FY 2023 Dec 31, 2023 10-K ↗ | FY 2022 Dec 31, 2022 10-K ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $1.30M | $200.00K | $1.80M | — |
| Depreciation Expense (USD) | $2.48M | $2.29M | $1.19M | — |
| Net Income, GAAP (USD) | $-140.06M | $1.69B | $-241.36M | — |
| Operating Cash Flow (USD) | $-129.79M | $-194.41M | $-193.31M | — |
Secondary lens
Benchmark Lens
Compare INBX against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare INBX against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for INBX
No bullish signals detected
Debt to Equity is concerning (bottom quartile)
Percentile Rankings
How INBX compares to all companies
Peer Comparison
INBX vs similar peers
Compare INBX with peers
Stack INBX against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 1 week ago 4 years · 14 quarters